Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
7.67
+0.24 (3.23%)
At close: Nov 26, 2025, 4:00 PM EST
7.56
-0.11 (-1.43%)
After-hours: Nov 26, 2025, 6:14 PM EST
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $7.61M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $109.23M, up 103.75% year-over-year. In the year 2024, Wave Life Sciences had annual revenue of $108.30M, down -4.42%.
Revenue (ttm)
$109.23M
Revenue Growth
+103.75%
P/S Ratio
11.52
Revenue / Employee
$379,271
Employees
288
Market Cap
1.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
| Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
| Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
| Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
| Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
WVE News
- 15 days ago - These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results - Benzinga
- 16 days ago - Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 19 days ago - Wave Life Sciences to Present at Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025 - GlobeNewsWire
- 22 days ago - Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025 - GlobeNewsWire
- 25 days ago - Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript - Seeking Alpha
- 4 weeks ago - Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day - GlobeNewsWire